

SCIENTIFIC REPORTS



OPEN

The corneal subbasal nerve plexus and thickness of the retinal layers in pediatric type 1 diabetes and matched controls

Aline Götze¹, Sophie von Keyserlingk², Sabine Peschel¹, Ulrike Jacoby², Corinna Schreiber², Bernd Köhler³, Stephan Allgeier³, Karsten Winter⁴, Martin Röhlig⁵, Anselm Jünemann¹, Rainer Guthoff⁶, Oliver Stachs¹ & Dagmar-C. Fischer²

Optical coherence tomography (OCT) of the retina and corneal confocal laser scanning microscopy (CLSM) of the subbasal nerve plexus (SBP) are noninvasive techniques for quantification of the ocular neurodegenerative changes in individuals with type 1 diabetes mellitus (T1DM). In adult T1DM patients these changes are hardly related to T1DM only. Instead, ageing and/or lifestyle associated comorbidities have to be considered as putative confounding variables. Therefore, we investigated pediatric T1DM patients ($n = 28$; 14.2 ± 2.51 y; duration of disease: 5.39 ± 4.16 y) without clinical signs of diabetic retina disease, neuropathy, vasculopathy or nephropathy and compared our findings with those obtained in healthy controls ($n = 46$; 14.8 ± 1.89 y). The SBP was characterized by the averaged length, thickness, and tortuosity of nerve fibers as well as the number of branching and connecting points. OCT was used to determine the total thickness of the retina (ALL) and the thickness of each retinal layer. Both methods revealed signs of early neurodegenerative changes, e.g. thinning of distinct retinal layers at the pericentral ring and shortening of corneal nerve fibers that are already present in pediatric T1DM patients. Standardization of instruments and algorithms are urgently required to enable uniform comparison between different groups and define normative values to introduce in the clinical setting.

Type 1 diabetes mellitus (T1DM) is one of the most common metabolic disorders in childhood and affects nearly 15 million children worldwide¹. On the long run, children with T1DM experience an increased risk of complications and comorbidities, i.e. vascular, renal, neurological and ophthalmological diseases. Since the onset of the disease in the vast majority of T1DM patients occurs during childhood, these patients are at risk to suffer from diabetes-related complications already at young adulthood².

Contrasting with the rather high sensitivity of the retina towards metabolic changes, virtually all forms of retinopathies remain asymptomatic for a long time³. There is increasing evidence that retinal neurodegeneration precedes diabetic retinopathy (DR) with first signs of microaneurysms³⁻⁷.

Optical coherence tomography (OCT) was introduced as a powerful tool for imaging and quantitative analysis of the retina⁸. OCT provides a cross-sectional view of the retina that allows discrimination and characterization of individual layers within the retina. Very recently, OCT revealed distinct but significant thinning of retinal layers in adults as well as adolescents and young adults suffering from T1DM^{3,9}.

Diabetes can impair corneal sensitivity and diabetic neuropathy may also influence the subbasal nerve plexus (SBP) of the cornea^{10,11}. Furthermore, it is already known that the condition of the SBP worsens not only with duration of the disease but also when glycemic control is insufficient and during the progression of diabetic polyneuropathy (DPN)¹²⁻¹⁴. In fact, confocal laser scanning microscopy (CLSM) revealed significant changes of the

¹Department of Ophthalmology, Rostock University Medical Center, Rostock, Germany. ²Department of Pediatrics, Rostock University Medical Center, Rostock, Germany. ³Institute for Applied Computer Science, Karlsruhe Institute of Technology (KIT), Karlsruhe, Germany. ⁴Institute for Anatomy, University of Leipzig, Leipzig, Germany. ⁵Institute of Computer Science, University of Rostock, Rostock, Germany. ⁶Department of Ophthalmology, Medical Faculty, Heinrich-Heine University, Düsseldorf, Germany. Aline Götze, Sophie von Keyserlingk, Oliver Stachs and Dagmar-C. Fischer contributed equally to this work. Correspondence and requests for materials should be addressed to D.-C.F. (email: dagmar-christiane.fischer@med.uni-rostock.de)

	CLSM		OCT and CLSM	
	Patients (10 f/18 m)	Controls (28 f/18 m)	Patients (10 f/16 m)	Controls (16 f/14 m)
Age [year]	14.2 ± 2.54	14.8 ± 1.89	14.5 ± 2.23	14.5 ± 1.98
Height [SDS]	0.06 ± 0.88	0.58 ± 1.20	0.15 ± 0.89	0.66 ± 1.20
Weight [SDS]	0.23 ± 0.93	0.46 ± 1.00	0.31 ± 0.97	0.59 ± 0.94
BMI [SDS]	0.25 ± 0.92	0.26 ± 0.84	0.30 ± 0.96	0.37 ± 0.80
BP _{sys} [SDS]	1.94 ± 1.17*	1.27 ± 1.16*	1.95 ± 1.20	1.39 ± 1.18
BP _{dias} [SDS]	0.89 ± 0.74*	0.36 ± 0.88*	0.90 ± 0.76	0.50 ± 0.97
Duration of disease [year]	4.23 (1.2–15.5)		4.44 (1.2–15.5)	
Mean daily insulin dosage [IU/kg]	0.38 ± 0.15		0.39 ± 0.14	
Actual HbA _{1c} [%]	8.73 ± 2.00		8.96 ± 1.86	
Mean HbA _{1c} [%]	8.64 ± 1.53		8.73 ± 1.51	

Table 1. Anthropometric and clinical characteristics of patients and controls. Results are given as mean ± standard deviation and as median (min, max) for all participants undergoing CLSM and for the subgroups undergoing OCT and CLSM. *Significant difference between patients and controls.

SBP in diabetic patients regardless of concomitant DPN^{7,14–19}. However, quantitative analysis of CLSM images is still a challenging task as it requires sophisticated software tools to describe the SBP in terms of nerve fiber length, density, connectivity and tortuosity^{7,14,19–21}.

However, there are still many open questions regarding the noted changes at the level of the SBP and retinal layers in T1DM patients relative to controls, since the significance of the OCT and CLSM findings is limited⁹. Whereas a wide variety of comorbidities have to be considered as putative confounding variables in adult T1DM patients, this is less relevant in pediatric T1DM patients. Consequently, cross-sectional studies in children and adolescents can open the window and may contribute to our understanding of neurodegenerative eye diseases. We hypothesize that in otherwise healthy pediatric T1DM patients, signs of neurodegenerative disease are already detectable with OCT and/or CLSM. In the present study, we report the results of a cross-sectional study obtained by applying both techniques simultaneously in a large cohort of pediatric T1DM patients and healthy controls matched for sex and age.

Results

A total of 28 patients (18 males) with a mean age of 14.2 ± 2.51 years and 46 healthy volunteers (18 males) with a mean age of 14.8 ± 1.89 years consented to participate and CLSM of the eye was performed. Out of these, a subgroup of 26 patients (16 males) and 30 controls (14 males) received an additional OCT. Anthropometric and clinical data are given in Table 1. While anthropometric characteristics and age were fairly comparable between patients and controls, office blood pressure (BP) was significantly higher in patients compared to controls. Insulin was administered via multiple daily insulin injections (MDI) to 16 (15) patients and via continuous subcutaneous insulin infusion (CSII) to 12 (11) patients undergoing CLSM and OCT, respectively. Categorization of patients according to therapy revealed no differences with respect to the (i) distribution of boys and girls, (ii) duration of disease, (iii) daily insulin dosage, and (iv) glycemic control in terms of actual and mean HbA_{1c} (Supplemental Table 1). In all participants, visus was 1.0 or better and corneal sensitivity was well preserved (data not shown). At the time of enrolment, patients had neither clinical signs of diabetic vasculopathy, nephropathy or neuropathy nor mentioned such symptoms during the interview.

OCT and analysis of the retina. Typical images taken from the retina of a T1DM patient and a healthy control together with segmentation of the retinal layers by means of OCT are shown in Fig. 1. In healthy controls, the thickness of the retinal layers at all predefined sites of measurement turned out to be independent of age and sex. Therefore, these two variables were not considered for interpretation of the results. Total retinal thickness, as well as the thickness of individual retinal layers at the fovea and throughout the peripheral region, was quite similar in patients and controls (Supplemental Table 2). By contrast, within the pericentral ring, significant thinning of the retinal nerve fiber layer (RNFL), the ganglion cell layer (GCL), and total retinal thickness (ALL) was noted in T1DM patients compared to controls (Fig. 2). The thickness of the retinal layers was not associated with HbA_{1c} or duration of disease. Concerning the insulin regimen, patients on CSII revealed significantly thinner foveal GCL, inner plexiform layer (IPL), inner nuclear layer (INL), outer plexiform layer (OPL), and ALL compared to those on MDI (Table 2). Furthermore, in patients on CSII, foveal OPL and ALL was even significantly thinner compared to healthy controls. By contrast, in patients on MDI, none of these parameters was significantly different to healthy controls. However, OPL at the pericentral ring was significantly thinner in patients on MDI compared to those using CSII (Table 2).

Within the study population, the foveal thickness of RNFL, GCL, IPL and INL were strongly associated among themselves as well as with the total thickness of the retina (each $R \geq 0.74$ and $p < 0.001$). Within the pericentral and peripheral area, the thickness of the GCL and IPL (each $R \geq 0.82$ and $p < 0.001$) were strongly associated. The thickness of the outer nuclear layer (ONL), the OPL or the retinal pigment epithelium (RPE) turned out to be independent of the dimension of the inner retinal layers.




Figure 1. Representative images from a T1DM patient (left) and control (right). Automatically generated thickness maps and segmented boundaries of ganglion cell layer and the inner plexiform layer were presented.

CLSM and characteristics of the SBP. The SBP was analyzed in all participants and representative images were shown in Fig. 3. Corneal nerve fiber length (CNFL), corneal nerve single fiber length (CNSFL), and corneal nerve fiber thickness (CNFTh) were significantly lower and corneal nerve fiber tortuosity (CNFTo) is significantly higher in patients compared to healthy controls. Corneal nerve fiber density (CNFD), corneal nerve fiber branch density (CNBD), and the number of corneal nerve connecting points (CNCP) did not differ between groups (Fig. 4 and Table 3). In healthy controls, none of these parameters describing the SBP were related to age or sex. By contrast, in T1DM patients, CNFTo was significantly higher in females compared to males ($0.086 \mu\text{m}^{-1}$ (range: $0.083\text{--}0.090 \mu\text{m}^{-1}$) vs. $0.083 \mu\text{m}^{-1}$ (range: $0.076\text{--}0.094 \mu\text{m}^{-1}$); $p < 0.01$). Furthermore, CNCP tended to be lower in female compared to male T1DM patients (60.75mm^{-1} (range: $10.57\text{--}111.5 \text{mm}^{-1}$) vs. 87.99mm^{-1} (range: $29.7\text{--}159.0 \text{mm}^{-1}$); $p < 0.05$). Although none of the parameters describing the SBP was associated with the HbA_{1c} or duration of disease, the difference might, at least partially, reflect that duration of disease was slightly longer in female compared to the male patients (5.19 years vs. 2.79 years; $p = 0.10$). The parameters describing the SBP were similar in patients on MDI and CSII (data not shown). In healthy controls, CNFL was strongly associated with CNFD, CNBD (each $R = 0.95$ and $p < 0.001$) and CNCP ($R = 0.65$, $p < 0.001$), while CNFTh and CNFTo were virtually independent of either one of these parameters used to describe the SBP. By contrast, in T1DM patients, CNFTh is related to CNFL ($R = 0.411$, $p < 0.05$) and CNCP ($R = 0.544$; $p < 0.005$). Furthermore, CNFL decreases reciprocally to tortuosity ($R = -0.61$; $p \leq 0.001$).

Correlation analysis of OCT and CLSM data. Within healthy controls, data obtained by OCT and CLSM were not associated at all. By contrast, in T1DM patients, the thickness of the RNFL at the peripheral area as well as the thickness of the INL at the pericentral area turned out to be significantly associated with CNFD and CNCP, respectively (Fig. 5). Although neuronal changes at the level of the retina and cornea turned out to be unrelated to glycemic control and duration of disease, CNFTo increases whereas foveal INL and pericentral RNFL thickness each decreases with insulin basal dosage rise (Fig. 6).

Discussion

Within this cross-sectional study, we sequentially applied OCT and CLSM to pediatric T1DM patients and healthy age-matched controls. Besides separate interpretation of OCT and CLSM data relative to the underlying disease, our approach enabled us to analyze the association of both in healthy and diseased children. This is especially interesting, as early signs of DR or DPN are rarely seen in pediatric T1DM patients with current pediatric daily care.

Within our patient cohort, OCT revealed significant thinning of the RNFL, the GCL, and ALL at the pericentral ring. These findings were not related to HbA_{1c} or duration of disease. Our results correspond with very recent reports and support the current notion that retinal neurodegeneration occurs early and prior to vascular retinopathy^{3–5,22–26}. Neuronal apoptosis and the loss of ganglion cell bodies are considered to be mainly responsible for the thinning of the inner retinal layers^{5,6,26}. In line with this, our data also point to the higher vulnerability of the RNFL and GCL relative to the other retinal layers, especially in the absence of any signs of diabetic vascular retinopathy. Interestingly, patients on CSII therapy presented with significantly thinner foveal retinal




Figure 2. Significant differences (each $p < 0.05$) of the pericentral thickness of the RNFL (A), the GCL (B) and ALL (C) in patients (black circles) and controls (blue circles).

layers than those using MDI therapy despite comparable daily basal insulin dosages, glycemic control and disease duration. Whether this finding is due to sampling bias, the incidence of diabetic ketoacidosis or related to the insulin preparation, i.e. pharmacological properties and half-life of insulin applied as bolus (MDI) or continuously (CSII), remains to be elucidated. In streptozotocin-induced diabetic rats, insulin reduces retinal apoptosis thereby preserving morphology of the tissue⁵. Although CSII compared to MDI has been associated with better glycemic control, we obtained evidence that retinal thinning at the fovea is more pronounced in patients on CSII, whereas the pericentral OPL was apparently more affected in patients on MDI. Additional studies are required to verify these findings.

	CSII (5 f/6 m)	MDI (6 f/9 m)	p
Foveal thickness of the			
GCL [μm]	15.33 (10.00–21.67)	18.67 (14.00–42.67)	0.038
IPL [μm]	20.00 (17.67–26.33)	25.00 (20.33–38.33)	0.035
INL [μm]	17.67 (12.67–24.67)	20.33 (17.00–32.67)	0.021
OPL [μm]	25.67* (16.33–32.33)	29.33 (21.33–36.33)	0.038
ALL [μm]	270.7* (232.0–302.0)	290.0 (256.7–327.3)	0.024
pericentral thickness of the			
OPL [μm]	34.58 (30.08–40.50)	32.58 (28.42–35.08)	0.029

Table 2. Thickness of the foveal retinal layers and of the pericentral OPL in patients on MDI and CSII therapy. Data are given as median and range. ALL, total thickness of retina; GCL, ganglion cell layer; IPL, inner plexiform layer; INL, inner nuclear layer; OPL, outer plexiform layer. * $p < 0.05$ compared to controls.




Figure 3. The typical mosaic image of the SBP of a patient (A), healthy control (B) and schematic representation of skeletonized images used for characterization of the SBP in patients (C) and healthy controls (D).

Within our patient cohort, we noted significant inverse associations between basal insulin dosage and either the thickness of the pericentral RNFL or the thickness of the foveal INL. Apart from effects related to the insulin regimen, glycemic variability is more pronounced in pediatric T1DM patients on MDI compared to CSII²⁷. Hyperglycemic episodes are capable to activate alternative pathways finally leading to microvascular complications^{27,28}. However, retinal neurodegeneration is an early event and most likely precedes microvascular damage, i.e. apoptosis of retinal neural cells impairs the blood-retinal barrier with subsequent development of microangiopathy and finally thickening of the retinal layer^{29–32}. Longitudinal studies are required to investigate the time course of retinal changes relative to the progression of the disease and the degree of glycemic variability in detail. Furthermore, data from morphological and functional investigations are required for better interpretation of the clinical relevance of morphological changes.

Similar to OCT, CLSM revealed significant neuronal changes in our T1DM patients. Besides a reduction of CNFL, CNSFL, and CNFTh, an increased CNFTo was noted and CNFTo increases as either CNFL or CNCP decrease. These findings are in agreement with those seen in adult DM patients and point to neurodegenerative changes early during the time course of the disease^{7,9,12,14,15,18,19,33}. To the best of our knowledge, the SBP has been investigated thus far only in a very small group of pediatric DM patients³⁴. Although the anthropometric and clinical characteristics regarding the duration of disease and glycemic control of pediatric patients enrolled in either study are fairly comparable, the results are not. Most likely, these differences are due to different experimental




Figure 4. Significant differences between CNFL (A) $p < 0.05$, CNFTo (B) $p < 0.01$, CNSFL (C) $p < 0.005$ and CNFTh (D) $p < 0.005$ in patients (black circles) and controls (blue circles).

	Patients (10 f/18 m)	Controls (28 f/18 m)	p
Results for			
CNFD [mm^{-2}]	249 (84.0–503)	252 (126–641)	0.832
CNBD [mm^{-2}]	135 (27.9–302)	123 (52.4–397)	0.798
CNCP [mm^{-2}]	73.9 (10.6–159)	77.3 (22.6–153)	0.196

Table 3. Results of the CLSM in pediatric T1DM patients and healthy controls. CNFD, corneal nerve fiber density; CNBD, corneal nerve fiber branch density; CNCP, corneal nerve connecting points.

settings, the local variability of the SBP, the number and localization of image stacks taken per eye and subsequent processing of the data^{20,21,35–37}.

The strong correlation between neurodegenerative changes at the level of retina and cornea, the absence of any clinically relevant signs of DR or DPN together with the missing association between neurodegenerative changes and duration of disease or glycemic control point to a rather high vulnerability and maladaptive response of these structures to diabetes-related metabolic changes²⁹. Recently, we demonstrated an impaired endothelial vasodilation secondary to local heating in pediatric T1DM patients by means of laser Doppler fluximetry for assessment of skin microcirculation³⁸. This effect was due to an impaired axon reflex mediating neurogenic vasodilation³⁸. Of note, this was seen in pediatric T1DM patients without any clinical signs of DR or DPN³⁸.

Although we obtained evidence that subtle neurodegenerative changes are already detectable in pediatric T1DM patients, our study has limitations. Unfortunately, documentation of diabetic ketoacidosis is not part of the routine diagnostic pipeline in our outpatient clinic and OCT became available for this study only after the start of the subject enrolment. Even though we requested all the subjects (that were already examined with CLSM) to




Figure 5. Correlations between CNFD and the peripheral RNFL thickness (A) and between CNCP and the pericentral INL thickness (B) in T1DM patients. A, $R = 0.52$, $p < 0.01$; B, $R = 0.54$, $p < 0.01$.

undergo an additional OCT examination, 2 of the patients and 14 controls refused to participate. Due to this, we could investigate a rather small number of patients and describe morphological changes, only. Comorbidities are usually less relevant in pediatric patients and clinical signs of DR, DPN or vasculopathy were not detectable at all. However, to clearly link neurodegenerative changes to the time course of the disease, carefully designed longitudinal studies along with a concomitant assessment of morphological and functional changes relative to long-term glycemic control and the therapeutic regimen are required.

Symptomatic DR or DPN are rarely seen in children with T1DM and daily care clinical techniques are not sensitive enough to detect neuropathies at an early stage when improvement of therapy has the potential to prevent progression or even to promote nerve regeneration^{34,39–41}. In this regard, our data indicate that OCT and CLSM both are valuable tools to detect early neurodegenerative changes. However, standardization of instruments, algorithms and data processing is an immediate prerequisite to enable data comparison between different groups. Defining the normative values of various retinal and SBP parameters may further assist in the secure transition of these methodologies into the clinical setting.

Material and Methods

Study design. The study received appropriate ethics committee approval from the institutional review board (Rostock University Medical Centre Ethics committee) in accordance with the Declaration of Helsinki. All examinations were done in accordance with the relevant guidelines. Subjects and/or their parents gave written and informed consent for participating in the study. All participants received a voucher to appreciate for the additional time spent in the hospital environment.

Pediatric T1DM patients being treated at the university between October 2012 and December 2013 were invited to participate. Healthy age-matched controls were recruited from different schools in Rostock. *Inclusion criteria:* age 6–18 years, duration of disease at least 12 months, C-peptide below 0.3 nmol/l, stable therapeutic regimen with either multiple daily insulin injections (MDI) or continuous subcutaneous insulin infusions (CSII, pump therapy) for at least 3 months. *Exclusion criteria:* any case of febrile illness during the last three months, chronic auto-inflammatory disease (e.g. Crohn's disease, rheumatoid arthritis), hepatitis, HIV, glucocorticoid treatment, liver-, renal-, or cardiac failure, hereditary dyslipidemia, neurological diseases including idiopathic small fibre neuropathy, clinical evidence of diabetic peripheral neuropathy, limited ability to cooperate, pregnancy, tumoral diseases or ophthalmological diseases especially myopia of more than 6 diopters, corneal and retinal disorders.

Methods

All participants were seen in our outpatient clinic. Demographic and clinical data were gathered by interview and chart review (i.e. duration of disease, mode of therapy, mean daily insulin dosages, mean HbA_{1c} during the last year). A trained physician measured weight and height using electronic scales and a fixed stadiometer. Office blood pressure (BP) was measured according to the updated Task Force Report on high blood pressure by using an oscillometric device (Dinamap 1846SX; Critikon, Tampa, USA). Calculations of individual age- and sex-related standard deviation scores (SD scores) for height, weight, BMI and BP were done as previously described^{42,43}.




Figure 6. Foveal INL thickness (A), pericentral RNFL thickness (B) and CNFTo (C) relative to the basal insulin dosage in T1DM patients. A, $R = -0.48$, $p < 0.05$; B, $R = -0.43$, $p < 0.05$; C, $R = 0.55$, $p < 0.005$.

Laboratory and clinical data. In patients, the actual HbA_{1c} expressed as a percentage of total hemoglobin and blood glucose levels were determined in the institute laboratory. The mean HbA_{1c} during the last 12 months and the actual mean insulin dosage per day and body weight were calculated.

Ophthalmological status. All of the patients underwent a complete ophthalmologic examination, i.e. determination of visual acuity, intraocular pressure and slit-lamp examination in mydriatic funduscopy. Patients and controls underwent OCT (Spectralis; Heidelberg Engineering GmbH, Heidelberg, Germany) for analysis of the retina, corneal esthesiometry and CLSM (HRTII + RCM; Heidelberg Engineering GmbH, Heidelberg, Germany) for analysis of the SBP. All ophthalmological tests were performed by the same experienced ophthalmologist (SP) for all study participants.

Optical coherence tomography and analysis of the retina. Unilateral spectral-domain OCT was performed by the same experienced ophthalmologist (SP) for all study participants essentially as described previously⁴⁴. All examinations were done in triplicate and the average of the results was used for subsequent analysis. This approach allowed mapping the macula thickness and for subsequent quantitative image analysis three circular segments centered at the fovea were separated automatically according to the ETDRS grid, i.e. a central, pericentral and a peripheral ring with outer diameters of 1 mm, 3 mm and 6 mm, respectively⁴⁵. Furthermore, the pericentral and peripheral areas were subdivided into quadrants (temporal, superior, nasal and inferior). Within each subfield, the retinal thickness (ALL), the retinal nerve fiber layer (RNFL), the ganglion cell layer (GCL), the

inner nuclear layer (INL), the inner plexiform layer (IPL), the outer plexiform layer (OPL), the outer nuclear layer (ONL), the retinal pigment epithelium (RPE) and the photoreceptor layer (PR) were discriminated. For each layer, the thickness was measured fully automatically at the localizations indicated using the algorithm provided by the manufacturer. Subsequently, data derived for each of the quadrants from the pericentral and peripheral ring were averaged. Thus, per layer three values reflecting the thickness at the fovea, the pericentral and peripheral area were obtained.

Corneal esthesiometry. Corneal esthesiometry was carried out using the Cochet-Bonnet esthesiometer (Luneau Ophthalmology, France). The nylon monofilament had a diameter of 0.12 mm and a fully extended length of 60 mm. The central, superior, inferior, nasal, and temporal cornea was touched once on each eye, beginning at a filament length of 60 mm. If a positive answer was not detected the filament length was shortened in steps of 5 mm each time and the procedure was repeated until there was a positive response. Corneal sensation was calculated as the mean obtained from the five corneal areas on each eye.

In vivo confocal laser-scanning microscopy and analysis of the corneal subbasal nerve plexus. For unilateral *in vivo* examination of the cornea, the Heidelberg Retina Tomograph (HRT II) in combination with the Rostock Cornea Module (RCM) was used essentially as described previously^{46,47}. Both eyes were anesthetized (Proparacaine 0.5% eye drops; Ursapharm, Saarbrücken, Germany) and covered with Vidisc gel (Bausch & Lomb/Dr. Mann Pharma, Berlin/Germany; refractive index 1.35). To prevent eye movements, the patients were asked to fixate one spot with the unexamined eye.

Imaging in the central region (at or close to the corneal apex and more than 0.5 mm apart from the inferior whorl) was performed using a dedicated scan modality at the level of basal cells, SBP, Bowman's membrane and anterior stroma described earlier⁴⁷. At least three scans per region and patient were recorded. The total duration of *in vivo* CLSM was about 15 minutes per patient. Subsequently, the SBP layer was detected automatically in each recorded depth scan and a mosaic image of the SBP was generated and submitted to quantitative image analysis^{21,47,48}. The following SBP parameters were determined: corneal nerve fiber length (CNFL), defined as the total length of all nerve fibers per unit area (mm/mm²); corneal nerve fiber density (CNFD), defined as the number of nerve fibers per unit area (n/mm²); corneal nerve branch density (CNBD), defined as the number of branching points per unit area (n/mm²); average weighted corneal nerve fiber tortuosity (CNFTo), reflecting variability of nerve fiber directions and defined as absolute nerve fiber curvature/nerve fiber length (per μm); corneal nerve connection points (CNCp), defined as the number of nerve fibers crossing the area boundary (connections/mm²); average corneal nerve single-fiber length (CNSFL), defined as the average length of nerve fibers (μm); and average weighted corneal nerve fiber thickness (CNFT_h), measured as mean thickness perpendicular to the nerve fiber course (μm)^{21,47,49}.

Statistical analysis. For statistical analysis, the SPSS Software package, version 22.0 (SPSS GmbH, Munich, Germany), was used. Normal distribution was evaluated by the Kolmogorov-Smirnov test and comparison between groups was done using Student's t-test or Mann-Whitney U test, if appropriate. For computation of correlations, Spearman's rho test was used. All p-values are two-sided and a p-value below 0.05 was considered significant. Data are given as mean \pm standard deviation (sd) or median and range, where appropriate.

Data availability statement. The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

References

- Pourabbasi, A., Tehrani-Doost, M., Ebrahimi Qavam, S. & Larijani, B. Evaluation of the correlation between type 1 diabetes and cognitive function in children and adolescents, and comparison of this correlation with structural changes in the central nervous system: a study protocol. *BMJ Open* **6**, e007917, <https://doi.org/10.1136/bmjopen-2015-007917> (2016).
- Roche, E. F. *et al.* Is the incidence of type 1 diabetes in children and adolescents stabilising? The first 6 years of a National Register. *Eur J Pediatr* **175**, 1913–1919, <https://doi.org/10.1007/s00431-016-2787-6> (2016).
- Chen, Y., Li, J., Yan, Y. & Shen, X. Diabetic macular morphology changes may occur in the early stage of diabetes. *BMC Ophthalmol* **16**, 12, <https://doi.org/10.1186/s12886-016-0186-4> (2016).
- Bialosterski, C. *et al.* Decreased optical coherence tomography-measured pericentral retinal thickness in patients with diabetes mellitus type 1 with minimal diabetic retinopathy. *Br J Ophthalmol* **91**, 1135–1138, <https://doi.org/10.1136/bjo.2006.111534> (2007).
- Barber, A. J. A new view of diabetic retinopathy: a neurodegenerative disease of the eye. *Prog Neuropsychopharmacol Biol Psychiatry* **27**, 283–290, [https://doi.org/10.1016/S0278-5846\(03\)00023-X](https://doi.org/10.1016/S0278-5846(03)00023-X) (2003).
- Villarroel, M., Ciudin, A., Hernandez, C. & Simo, R. Neurodegeneration: An early event of diabetic retinopathy. *World J Diabetes* **1**, 57–64, <https://doi.org/10.4239/wjd.v1.i2.57> (2010).
- Zhivov, A. *et al.* Imaging and quantification of subbasal nerve plexus in healthy volunteers and diabetic patients with or without retinopathy. *PLoS One* **8**, e52157, <https://doi.org/10.1371/journal.pone.0052157> (2013).
- Fujimoto, J. G., Pitris, C., Boppart, S. A. & Brezinski, M. E. Optical coherence tomography: an emerging technology for biomedical imaging and optical biopsy. *Neoplasia* **2**, 9–25 (2000).
- De Clerck, E. E. *et al.* New ophthalmologic imaging techniques for detection and monitoring of neurodegenerative changes in diabetes: a systematic review. *Lancet Diabetes Endocrinol* **3**, 653–663, [https://doi.org/10.1016/S2213-8587\(15\)00136-9](https://doi.org/10.1016/S2213-8587(15)00136-9) (2015).
- Rosenberg, M. E. *et al.* Corneal structure and sensitivity in type 1 diabetes mellitus. *Invest Ophthalmol Vis Sci* **41**, 2915–2921 (2000).
- Cai, D., Zhu, M., Petroll, W. M., Koppaka, V. & Robertson, D. M. The impact of type 1 diabetes mellitus on corneal epithelial nerve morphology and the corneal epithelium. *Am J Pathol* **184**, 2662–2670, <https://doi.org/10.1016/j.ajpath.2014.06.016> (2014).
- Dehghani, C. *et al.* Natural history of corneal nerve morphology in mild neuropathy associated with type 1 diabetes: development of a potential measure of diabetic peripheral neuropathy. *Invest Ophthalmol Vis Sci* **55**, 7982–7990, <https://doi.org/10.1167/iovs.14-15605> (2014).
- Edwards, K. *et al.* Utility of corneal confocal microscopy for assessing mild diabetic neuropathy: baseline findings of the LANDMark study. *Clin Exp Optom* **95**, 348–354, <https://doi.org/10.1111/j.1444-0938.2012.00740.x> (2012).

14. Ishibashi, F. *et al.* Corneal nerve fiber pathology in Japanese type 1 diabetic patients and its correlation with antecedent glycemic control and blood pressure. *J Diabetes Investig* **3**, 191–198, <https://doi.org/10.1111/j.2040-1124.2011.00157.x> (2012).
15. Kallinikos, P. *et al.* Corneal nerve tortuosity in diabetic patients with neuropathy. *Invest Ophthalmol Vis Sci* **45**, 418–422 (2004).
16. Pritchard, N. *et al.* Corneal sensitivity as an ophthalmic marker of diabetic neuropathy. *Optom Vis Sci* **87**, 1003–1008, <https://doi.org/10.1097/OPX.0b013e3181fd6188> (2010).
17. Pritchard, N. *et al.* Corneal sensitivity is related to established measures of diabetic peripheral neuropathy. *Clin Exp Optom* **95**, 355–361, <https://doi.org/10.1111/j.1444-0938.2012.00729.x> (2012).
18. Stem, M. S. *et al.* Differential reduction in corneal nerve fiber length in patients with type 1 or type 2 diabetes mellitus. *J Diabetes Complications* **28**, 658–661, <https://doi.org/10.1016/j.jdiacomp.2014.06.007> (2014).
19. Wang, E. F., Misra, S. L. & Patel, D. V. *In Vivo* Confocal Microscopy of the Human Cornea in the Assessment of Peripheral Neuropathy and Systemic Diseases. *Biomed Res Int* **2015**, 951081, <https://doi.org/10.1155/2015/951081> (2015).
20. Tavakoli, M. *et al.* Normative values for corneal nerve morphology assessed using corneal confocal microscopy: a multinational normative data set. *Diabetes Care* **38**, 838–843, <https://doi.org/10.2337/dc14-2311> (2015).
21. Winter, K. *et al.* Local Variability of Parameters for Characterization of the Corneal Subbasal Nerve Plexus. *Curr Eye Res* **41**, 186–198, <https://doi.org/10.3109/02713683.2015.1010686> (2016).
22. Bronson-Castain, K. W. *et al.* Early neural and vascular changes in the adolescent type 1 and type 2 diabetic retina. *Retina* **32**, 92–102, <https://doi.org/10.1097/IAE.0b013e318219deac> (2012).
23. El-Fayoumi, D., Badr Eldine, N. M., Esmael, A. F., Ghalwash, D. & Soliman, H. M. Retinal Nerve Fiber Layer and Ganglion Cell Complex Thicknesses Are Reduced in Children With Type 1 Diabetes With No Evidence of Vascular Retinopathy. *Invest Ophthalmol Vis Sci* **57**, 5355–5360, <https://doi.org/10.1167/iovs.16-19988> (2016).
24. Mendez, N., Kommana, S. S., Szirth, B. & Khouri, A. S. Structural Changes by Spectral Domain Optical Coherence Tomography in Patients With Type 1 Diabetes Mellitus. *J Diabetes Sci Technol* **10**, 271–276, <https://doi.org/10.1177/1932296815603371> (2015).
25. van Dijk, H. W. *et al.* Selective loss of inner retinal layer thickness in type 1 diabetic patients with minimal diabetic retinopathy. *Invest Ophthalmol Vis Sci* **50**, 3404–3409, <https://doi.org/10.1167/iovs.08-3143> (2009).
26. van Dijk, H. W. *et al.* Decreased retinal ganglion cell layer thickness in patients with type 1 diabetes. *Invest Ophthalmol Vis Sci* **51**, 3660–3665, <https://doi.org/10.1167/iovs.09-5041> (2010).
27. Schreiver, C. *et al.* Glycaemic variability in paediatric patients with type 1 diabetes on continuous subcutaneous insulin infusion (CSII) or multiple daily injections (MDI): a cross-sectional cohort study. *Clin Endocrinol (Oxf)* **79**, 641–647, <https://doi.org/10.1111/cen.12093> (2013).
28. Brownlee, M. The pathobiology of diabetic complications: a unifying mechanism. *Diabetes* **54**, 1615–1625 (2005).
29. Antonetti, D. A. *et al.* Diabetic retinopathy: seeing beyond glucose-induced microvascular disease. *Diabetes* **55**, 2401–2411, <https://doi.org/10.2337/db05-1635> (2006).
30. Lieth, E., Gardner, T. W., Barber, A. J., Antonetti, D. A. & Penn State Retina Research, G. Retinal neurodegeneration: early pathology in diabetes. *Clin Exp Ophthalmol* **28**, 3–8 (2000).
31. Reis, A. *et al.* Neuroretinal dysfunction with intact blood-retinal barrier and absent vasculopathy in type 1 diabetes. *Diabetes* **63**, 3926–3937, <https://doi.org/10.2337/db13-1673> (2014).
32. Verbraak, F. D. Neuroretinal degeneration in relation to vasculopathy in diabetes. *Diabetes* **63**, 3590–3592, <https://doi.org/10.2337/db14-0888> (2014).
33. Pritchard, N. *et al.* Longitudinal assessment of neuropathy in type 1 diabetes using novel ophthalmic markers (LANDMark): study design and baseline characteristics. *Diabetes Res Clin Pract* **104**, 248–256, <https://doi.org/10.1016/j.diabres.2014.02.011> (2014).
34. Sellers, E. A. *et al.* The acceptability and feasibility of corneal confocal microscopy to detect early diabetic neuropathy in children: a pilot study. *Diabet Med* **30**, 630–631, <https://doi.org/10.1111/dme.12125> (2013).
35. Parissi, M. *et al.* Standardized baseline human corneal subbasal nerve density for clinical investigations with laser-scanning *in vivo* confocal microscopy. *Invest Ophthalmol Vis Sci* **54**, 7091–7102, <https://doi.org/10.1167/iovs.13-12999> (2013).
36. Allgeier, S. *et al.* A Novel Approach to Analyze the Progression of Measured Corneal Sub-Basal Nerve Fiber Length in Continuously Expanding Mosaic Images. *Curr Eye Res* **42**, 481–490, <https://doi.org/10.1080/02713683.2016.1221977> (2017).
37. Vagenas, D. *et al.* Optimal image sample size for corneal nerve morphometry. *Optom Vis Sci* **89**, 812–817, <https://doi.org/10.1097/OPX.0b013e31824ee8c9> (2012).
38. Heimhalt-El Hamriti, M. *et al.* Impaired skin microcirculation in paediatric patients with type 1 diabetes mellitus. *Cardiovasc Diabetol* **12**, 115, <https://doi.org/10.1186/1475-2840-12-115> (2013).
39. Blankenburg, M. *et al.* Childhood diabetic neuropathy: functional impairment and non-invasive screening assessment. *Diabet Med* **29**, 1425–1432, <https://doi.org/10.1111/j.1464-5491.2012.03685.x> (2012).
40. Tavakoli, M. *et al.* Corneal confocal microscopy detects improvement in corneal nerve morphology with an improvement in risk factors for diabetic neuropathy. *Diabet Med* **28**, 1261–1267, <https://doi.org/10.1111/j.1464-5491.2011.03372.x> (2011).
41. Tavakoli, M. *et al.* Corneal confocal microscopy detects early nerve regeneration in diabetic neuropathy after simultaneous pancreas and kidney transplantation. *Diabetes* **62**, 254–260, <https://doi.org/10.2337/db12-0574> (2013).
42. Kromeyer-Hauschild, K. *et al.* Perzentile für den body-mass-index für das Kindes- und Jugendalter unter Heranziehung verschiedener deutscher Stichproben. *Monatsschr Kinderheilkd* **149**, 807–818, <https://doi.org/10.1007/s001120170107> (2001).
43. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. *Pediatrics* **114**, 555–576 (2004).
44. Diabetic Retinopathy Clinical Research Network Writing, C. *et al.* Reproducibility of spectral-domain optical coherence tomography retinal thickness measurements and conversion to equivalent time-domain metrics in diabetic macular edema. *JAMA Ophthalmol* **132**, 1113–1122, <https://doi.org/10.1001/jamaophthalmol.2014.1698> (2014).
45. Grading diabetic retinopathy from stereoscopic color fundus photographs—an extension of the modified Airlie House classification. ETDRS report number 10. Early Treatment Diabetic Retinopathy Study Research Group. *Ophthalmology* **98**, 786–806 (1991).
46. Guthoff, R. F., Zhivov, A. & Stachs, O. *In vivo* confocal microscopy, an inner vision of the cornea - a major review. *Clin Exp Ophthalmol* **37**, 100–117, <https://doi.org/10.1111/j.1442-9071.2009.02016.x> (2009).
47. Ziegler, D. *et al.* Early detection of nerve fiber loss by corneal confocal microscopy and skin biopsy in recently diagnosed type 2 diabetes. *Diabetes* **63**, 2454–2463, <https://doi.org/10.2337/db13-1819> (2014).
48. Allgeier, S. *et al.* Image reconstruction of the subbasal nerve plexus with *in vivo* confocal microscopy. *Invest Ophthalmol Vis Sci* **52**, 5022–5028, <https://doi.org/10.1167/iovs.10-6065> (2011).
49. Holmes, T. J. *et al.* Automated software analysis of corneal micrographs for peripheral neuropathy. *Invest Ophthalmol Vis Sci* **51**, 4480–4491, <https://doi.org/10.1167/iovs.09-4108> (2010).

Acknowledgements

We thank Dr. Bhavani Kowtharapu for helpful advice. This work has been supported by the German Research Foundation (Project VIES).

Author Contributions

Study design and conduct: O.S. and D.C.F. Data collection: A.G., S.v.K., S.P., U.J. and C.S. Ophthalmological testing: S.P. Data analysis: B.K., S.A., K.W., M.R. and O.S. Data interpretation: A.G., S.v.K., A.J., R.G., O.S. and D.C.F. Drafting the manuscript: A.G., S.v.K., O.S. and D.C.F. Revising manuscript content and approving final version of the manuscript: A.G., S.v.K., S.P., U.J., C.S., B.K., S.A., K.W., M.R., A.J., R.G., O.S. and D.C.F.

Additional Information

Supplementary information accompanies this paper at <https://doi.org/10.1038/s41598-017-18284-z>.

Competing Interests: The authors declare that they have no competing interests.

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2017